RASMUS

RecruitingPhase 1

Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscle Health)

Effect of CagriSema, Semaglutide and Cagrilintide on Skeletal Muscle Insulin Sensitivity, Composition and Function

Lead sponsor

Novo Nordisk A/S

Assets

CagriSema / cagrilintide / Semaglutide

Listed sites

Recruiting sites

Enrollment

100

estimated

Study population

Obesity / overweight

Key I/E criterion

—

Primary endpoint

•Insulin-stimulated fluorodeoxyglucose (FDG) uptake in skeletal muscle

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07527195

Org study IDNN9838-8411

Secondary ID2025-522920-28European Medical Agency (EMA)

Secondary IDU1111-1321-8655World Health Organization (WHO)

Timeline

Milestones

Study start2026-04-10actual

Study first posted2026-04-14actual

Last update posted2026-05-07actual

Primary completion2028-04-28estimated

Study completion2028-06-09estimated

Assets

Investigational agents

CagriSema / cagrilintide Semaglutide

Study populations

Who this study enrolls

Obesity / overweight

Eligibility

Who can enroll

Minimum age50 Years

Maximum age70 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Male or female.

•Age 50-70 years (both inclusive) at the time of signing the informed consent.

•Body Mass index (BMI) between 30.0 kilograms per square meter (kg/m^2) and 39.9 kg/m^2 (both inclusive) at screening (V1).

•Excess body weight should be due to excess adipose tissue, as judged by the investigator.

•Participant has a wish to lose at least 25 percentage (%) of body weight within 52 weeks of treatment.

Exclusion criteria

•Any leg amputations.

•Female participants who are not postmenopausal at screening.

•Any clinically significant body weight change (greater than or equal to [>=] 5% self-reported change) or dieting attempts within 90 days before screening.

•Treatment with any glucagon-like peptide-1 (GLP-1) receptor agonist or a medication with GLP-1 activity within 90 days before screening.

Endpoints (3)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other (unclassified)

Glycemic / diabetes

1 endpoint

Primary/protocol endpoint

Change in insulin-stimulated fluorodeoxyglucose (FDG) uptake in skeletal muscle

Time frame:Baseline to Week 51

change from baseline, improvement

Other (unclassified)

2 endpoints

Secondary/protocol endpoint/low confidence

Change in insulin-stimulated FDG uptake in skeletal muscle

Time frame:Baseline to Week 20

change from baseline, improvement

Secondary/protocol endpoint/low confidence

Change in insulin-stimulated FDG uptake in skeletal muscle

Time frame:Baseline to Week 51

change from baseline, improvement

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.